Genetic Technologies Acquires Perlegen Assets

The Australian firm has acquired, among other assets, the BrevaGen breast cancer risk test, which it expects to launch in the second half of this year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories